Patent details

300475 Product Name: Combinatie van meningokokkaal groep A oligosacharide geconjugeerd met Corynebacterium diphtheriae CRM197 eiwit, meningokokkaal groep C oligosacharide geconjugeerd met Corynebacterium diphtheriae CRM197 eiwit, meningokokkaal groep W135 oligosacharide geconjugeerd met Corynebacterium diphtheriae CRM197 eiwit en meningokokkaal groep Y oligosacharide geconjugeerd met Corynebacterium diphtheriae CRM197 eiwit.

The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents

Basic Information

Publication number:
300475
Type:
Certificate
SPC Type:
Medical
Basic Patent Number:
EP1741442
Status:
Expired Art. 14 (a) of the EC Regulations
Application number:
300475
Procedural language:
Dutch
First Applicant Residence Country:
Switzerland (CH)

Marketing Authorization

Marketing Authorization Number:
EU/1/10/614/001
Marketing Authorization Type:
EEA
Marketing Authorization Date:
17/03/2010
Marketing Authorization Country:
European Union (EU)

Dates

Filing date:
14/01/2011
First Marketing Authorization date:
17/03/2010
Grant date:
23/03/2011
Activation date:
20/06/2022
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Registration date:
14/01/2011
SPC/SPC Extension Expiration Date:
16/03/2025
Lapsed By Expiration Date:
17/03/2025
Withdrawal date:
Revocation Date:
Invalidity Date:
Withdrawal Market Authorization Date:
Refusal Date:

Applicant/holder

From:
22/12/2021
 
 

 

Name:
GlaxoSmithKline Biologicals S.A.
Address:
Rue de l'Institut 89, 1330, Rixensart, Belgium (BE)

Historical Applicant/holder

From:
14/01/2011
To:
22/12/2021

 

Name:
Novartis AG
Address:
Lichtstrasse 35, 4056 BASEL, Switzerland (CH)

Agent

Name:
ir. F.A. Geurts c.s.
From:
21/02/2018
Address:
Octrooibureau Vriesendorp & Gaade B.V. Koninginnegracht 19, 2514 AB, Den Haag, Netherlands (NL)
To:

Publication

Bulletin

1

Bulletin Heading:
VRV
Journal edition number:
12/25
Publication date:
19/03/2025
Description:
Lapse or annulment

2

Bulletin Heading:
SPC
Journal edition number:
25/22
Publication date:
22/06/2022
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)

3

Bulletin Heading:
CO
Journal edition number:
05/22
Publication date:
02/02/2022
Description:
Changes in the Netherlands Patent Register

4

Bulletin Heading:
SPC
Journal edition number:
2011/13
Publication date:
30/03/2011
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)

5

Bulletin Heading:
SPC
Journal edition number:
2011/04
Publication date:
26/01/2011
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)

Deed

Change of owner(s)

Change Kind/ Decision Type:
Assignment
Deed Number:
RC202102715A
Date Registered:
22/12/2021
License Effective Date:
License Expiration Date:
Scope of License:
Deed Filer:
ir. F.A. Geurts c.s.
Journal Edition Number:
Text:
Deed Status:
Country Code:
Updated License Number:
Terminated License Number:

Added Owner(s)

Name:
GlaxoSmithKline Biologicals S.A.
Address:
Rue de l'Institut 89, 1330, Rixensart, Belgium (BE)

Changed Pledgee

Name:
Address:

Removed Usufructuary

Name:
Address:

Added Usufructuary

Name:
Address:

Changed Usufructuary

Name:
Address:

Annual Fee

Annual Fee(s) Due Date:
Annual Fee Number:
Last Annual Payment Date:
21/05/2024
Last Annual Fee Paid Number:
23
Last Annual Fee Paid Amount:
2000 Euro
Payer:
Anaqua Services
Filing date Document type Document Description Number of pages File Type
14/12/2018 SPC Documents Accompanying letter SPC 1 PDF /5/7/4/0/0/0400300475/docs/300475_12_supplprotectioncertificate20200908112108808.pdf
05/01/2016 SPC Documents Certificate SPC 1 PDF /5/7/4/0/0/0400300475/docs/300475_4_supplprotectioncertificate20200908111737374.pdf
05/01/2016 Outgoing Correspondence Decision grant 1 PDF /5/7/4/0/0/0400300475/docs/300475_6_outgoingcorrespondence20200908111435231.pdf
27/11/2015 SPC Documents Accompanying letter SPC 1 PDF /5/7/4/0/0/0400300475/docs/300475_1_supplprotectioncertificate20200908104911246.pdf
27/11/2015 SPC Documents Annex SPC 1 PDF /5/7/4/0/0/0400300475/docs/300475_10_supplprotectioncertificate20200908110158537.pdf
11/05/2011 SPC Documents Certificate SPC 1 PDF /5/7/4/0/0/0400300475/docs/300475_5_supplprotectioncertificate20200908104106918.pdf
11/05/2011 Outgoing Correspondence Outgoing Letter 1 PDF /5/7/4/0/0/0400300475/docs/300475_13_outgoingcorrespondence20110323.pdf
05/05/2011 SPC Documents Accompanying letter SPC 1 PDF /5/7/4/0/0/0400300475/docs/300475_0_supplprotectioncertificate20200908103342020.pdf
23/03/2011 Outgoing Correspondence Outgoing Letter 1 PDF /5/7/4/0/0/0400300475/docs/300475_7_outgoingcorrespondence20110323.pdf
23/03/2011 SPC Documents Certificate SPC 1 PDF /5/7/4/0/0/0400300475/docs/300475_8_supplprotectioncertificate20200908102906746.pdf
18/01/2011 Outgoing Correspondence Outgoing Letter 1 PDF /5/7/4/0/0/0400300475/docs/300475_14_outgoingcorrespondence20110118.pdf
14/01/2011 Application Form First filed application form 3 PDF /5/7/4/0/0/0400300475/docs/300475_2_applicationform20110114.pdf
14/01/2011 SPC Documents Accompanying letter SPC 1 PDF /5/7/4/0/0/0400300475/docs/300475_3_supplprotectioncertificate20200908101724592.pdf
14/01/2011 SPC Documents Marketing Authorization SPC 3 PDF /5/7/4/0/0/0400300475/docs/300475_9_supplprotectioncertificate20200908093306620.pdf
14/01/2011 SPC Documents Summary of the characteristics of the product 11 PDF /5/7/4/0/0/0400300475/docs/300475_11_supplprotectioncertificate20200908094150863.pdf